DocJuris has raised a $8 million series A. Photo via Getty Images

Houston-based DocJuris, a leader in AI contract review, announced the successful closure of its series A funding round by raising $8 million in new capital. This brings the total capital raised to date to $11.2 million.

"DocJuris AI has become an industry-leading platform that empowers enterprise legal, procurement, and sales teams to close deals faster while reducing risk," DocJuris CEO and Founder Henal Patel says in a news release. "With this funding, we will continue scaffolding our platform around generative AI, expand our customer success team, and grow our user base."

The most active venture capital firm in Texas Silverton Partners led the round with participation from previous investors Watertower Ventures, Surface Ventures, and Seed Round Capital.

Companies like Siemens, Dell, FedEx, Toyota, and Duke Energy already use DocJuris with its AI-powered contract negotiation software that automates imporrant tasks during the review, redlining, and negotiation of contracts. DocJuris uses a platform to screen third-party contracts in seconds, can redline clauses with playbook-compliant edits in one click, and also generate formatted track changes, exception tables, and amendments with a cloud-based application.

The Association of Corporate Counsel, awarded DocJuris the Value Champion Award in 2023 due to the reduced contract cycle times to minutes with AI.

“We wanted to replace repetitive, manual tasks and free up valuable time for our employees to focus on more impactful work,” lead attorney for Flex's Global Procurement and Supply Chain Iringo Csifo-Nagy adds. “To achieve this, we developed a turnkey solution for AI-driven contract reviews together with the DocJuris team."

In its first round of funding in 2021, DocJuris raised $3.2 million in seed capital.

DocJuris has raised its first round of venture funding to grow its team to keep up with demand for its legal software platform. Image courtesy of DocJuris

Houston B2B software company raises $3.2M in seed funding to grow team and product

money moves

A Houston-based software-as-a-service company that is revolutionizing the contract process has closed a round of funding this week.

DocJuris, founded in 2018, raised $3.2 million in seed funding led by New York-based RTP Seed with additional support from Houston-based Seed Round Capital, California-based Watertower Ventures, Maryland-based Crossbeam, and Remote First Capital.

It's the startup's first round of venture funding and Henal Patel, CEO of DocJuris, says he was looking for funds as well as support from investors who had experience with software and could open doors to new clients for the legal software.

"Our platform is designed to empower legal, sales, and procurement teams and corporations to negotiate and close contracts with greater speed and precision," Patel says. "The underlying mission is to solve the last-mile of contracting."

Henal Patel is CEO of DocJuris. Photo courtesy of DocJuris

The need for funding came at a time of growth, Patel says, as DocJuris was seeing more and more opportunities in light of the pandemic.

"As work has gone more remote, there's a greater need for teams to be able to collaborate on their contracts — instead of sending Word documents over email," he tells InnovationMap.

Within the contract optimization space, Patel says he sees a lot of opportunities for enhancing the experience for lawyers, business owners, contractors, and anyone who has to spend any amount of time on legal papers.

"One of our visions is to — in addition to providing the tactical tools we do to day — revisualize the way that people read contracts," Patel says. "Our platform enables the ability to improve the lives of the people who have to stare at contracts all day."

DocJuris is already hiring for a few positions across sales, customer service, and marketing, and Patel says he will continue to grow his remote team locally.

"We've been remote since before it was cool," Patel says, adding that all but one of his employees is based in Houston. "But we've been locally concentrated in Houston. We're planning on growing our team here in Houston, but keeping the team remote. We believe in Houston."

This week's Houston innovators to know includes Chris Buckner of Mainline and Austin Hill and Brad Jenkins of Seed Round Capital. Photos courtesy

3 Houston innovators to know this week

who's who

This week's Houston innovators to know have all grown or started a company during the COVID-19 pandemic — a bold choice. From an esports software entrepreneur to two serial founders looking to invest in the next generation of Houston tech startups.

Chris Buckner, co-founder and CEO of Mainline

With sports offline, esports startup Mainline has seen an opportunity for growth during the COVID-19 outbreak. Photo courtesy of Mainline

While Chris Buckner has found the isolation aspect of the pandemic challenging, he shares on this week's episode of the Houston Innovators Podcast that it's actually been an extremely exciting time for his esports tournament software startup, Mainline. This year, Mainline is poised to onboard over 100 schools to their system, and, while most of those schools were lined up before the pandemic, the process has been sped up.

"Everyone is looking for how to get sports, or esports, in front of people because everyone is just missing [sports] so much," Buckner says. "We've been very fortunate to work in the industry we do."

On campuses this past spring, basketball was cut short, baseball was canceled, and football's status is currently unknown. Colleges are looking for a way to connect with and engage students, Buckner says. And, Mainline has even been able to attract interest on the professional level. Read more and strea

Austin Hill and Brad Jenkins, co-founders of Seed Round Capital

Brad Jenkins and Austin Hill have announce the launch of a growth and invetment-focused incubator for startups called Seed Round Capital. Photos courtesy of Seed Round Capital

Brad Jenkins and Austin Hill wanted to create a firm that prioritized funding for growing tech startups in Houston, so they teamed up to launch Seed Round Capital, an investment and advisory firm based in Houston and for Houston-based startups. Rather than an accelerator model, the new firm will focus on long-term support for its portfolio companies.

"Our program helps startup founders fund and scale their businesses with management guidance from seasoned entrepreneurs. In addition, founders receive training on proven business methods specially formulated by Seed Round Capital, and access to funding," Hill says in a statement to InnovationMap.

Startups can apply online to be selected to receive mentoring from Jenkins, Hill, and a network of experts involved in — or previously involved in — Entrepreneurs' Organization (EO), a local group of business leaders. Once selected, Seed Round's startups will have access to office space at The Cannon. Read more.

Brad Jenkins and Austin Hill have announce the launch of a growth and invetment-focused incubator for startups called Seed Round Capital. Photos courtesy of Seed Round Capital

Exclusive: 2 serial entrepreneurs launch Houston startup incubator

funding focused

Two Houstonians with years of entrepreneurial and investing experience are starting a firm focused on advising and growing local technology startups.

Brad Jenkins and Austin Hill have announced the launch of Seed Round Capital, an investment and advisory firm based in Houston and for Houston-based startups. Rather than an accelerator model, the new firm will focus on long-term support for its portfolio companies.

"Our program helps startup founders fund and scale their businesses with management guidance from seasoned entrepreneurs. In addition, founders receive training on proven business methods specially formulated by Seed Round Capital, and access to funding," Hill says in a statement to InnovationMap.

Startups can apply online to be selected to receive mentoring from Jenkins, Hill, and a network of experts involved in — or previously involved in — Entrepreneurs' Organization (EO), a local group of business leaders. Once selected, Seed Round's startups will have access to office space at The Cannon.

"Because we recognize that every new business is unique in its journey, we are able to customize mentoring to suit each startup. Our expertise helps startups reduce risk, secure funding and grow faster than if they were doing this on their own," Jenkins says.

Jenkins has 25 years of software and technology startup experience and has served on the Houston board of EO. A Texas A&M University alumnus, he has a background in marketing and computer science. Hill's specialty includes distribution, contracting, real estate, and consumer-packaged goods. A University of Texas and West Point graduate, he won Rice University's Veterans Business Battle competition and organizes the EO's accelerator program.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."